Hormone Therapy for Prostate Cancer: ADT, Medicines, Side Effects and Duration

Hormone therapy is one of the most widely used systemic treatments for prostate cancer. It is also called androgen deprivation therapy (ADT) or androgen suppression therapy.

The basic principle is simple: prostate cancer cells often depend on male hormones, particularly testosterone and other androgens, to grow. Hormone therapy either lowers the amount of these hormones in the body or prevents them from stimulating cancer cells.

ADT may be used by itself in selected situations, but it is also frequently combined with radiation therapy, newer androgen receptor pathway medicines, chemotherapy, or other treatments depending on the stage and biology of the cancer.

For men with metastatic prostate cancer, modern treatment often involves more than traditional testosterone suppression alone. Current guidelines increasingly support combination approaches using ADT plus medicines such as abiraterone, enzalutamide, apalutamide or darolutamide in appropriate patients.

The duration can range from a few months to several years, or indefinitely in some men with advanced disease. There is no single duration that applies to every patient.

This is the ADT hub for the prostate cluster. It sits beside treatment without surgery, radiation, Lu-177 PSMA, PSMA PET and Prostate Cancer Treatment in India. GAF Healthcare planning ranges for hormone therapy in India are $1,000–$4,500; city pages such as Delhi NCR hormone therapy use the same national range unless a hospital issues a verified quotation.

International patients comparing medical oncologists and radiation oncologists commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Partner medical-oncology hospitals in Delhi NCR and Mumbai are a typical first filter.

Hormone therapy works by interfering with androgens, the group of hormones that includes testosterone. Most testosterone is produced by the testicles. Smaller amounts of androgen-related hormones are produced elsewhere, including the adrenal glands and, within prostate cancer cells, through other biochemical pathways.

Prostate cancer cells can use these hormones by activating the androgen receptor. Once activated, this pathway can stimulate cancer-cell growth. Hormone therapy therefore attacks the disease indirectly. Instead of destroying cancer cells like radiation or surgery, it changes the hormonal environment that the cancer needs to grow.

The two broad strategies are: reduce testosterone and androgen production, and block androgen signalling at the cancer cell. Modern prostate cancer treatment can use one or both approaches. How the cancer was staged is covered in Stages 1 to 4; how Grade Group is assigned is in Gleason Score and Grade Group.

ADT stands for androgen deprivation therapy. It is sometimes called androgen suppression therapy, hormonal therapy, hormone treatment, testosterone suppression or medical castration. The term “medical castration” is used because certain medicines can reduce testosterone to very low levels without surgically removing the testicles.

ADT should not be confused with every form of hormone-related treatment. Abiraterone, enzalutamide, apalutamide and darolutamide are often added to ADT in advanced disease because they interfere with the androgen pathway in different ways.

There are several points in the androgen pathway where treatment can intervene.

These different mechanisms explain why modern treatment may involve combinations rather than a single hormone medicine.

Hormone therapy is not automatically given to every man diagnosed with prostate cancer. Its role depends on cancer stage, PSA, Gleason score, Grade Group, lymph-node involvement, metastases, risk of recurrence, previous treatment, overall health, planned radiation or systemic treatment, and patient preferences.

ADT is commonly combined with radiation in selected men with unfavorable intermediate-risk, high-risk or locally advanced prostate cancer. Lowering androgen activity can make prostate cancer cells more vulnerable to radiation and can help control cancer outside the immediate radiation field.

The duration is not the same for everyone. Depending on the risk category and treatment strategy, ADT may be given for several months or for a longer period. For high-risk and locally advanced disease treated with radiation, long-term ADT has traditionally been used for approximately 2–3 years in appropriate patients. GAF Healthcare planning ranges include EBRT $1,000–$6,000+, IMRT $6,500–$14,500 and brachytherapy $5,500–$13,000 — billed separately from ADT.

A rising PSA may be the first indication of recurrence after surgery or radiation. Depending on the location and speed of recurrence, treatment may include salvage radiation, ADT, radiation plus ADT, newer androgen receptor pathway inhibitors or other systemic treatments. See Prostate Cancer Recurrence After Surgery.

When prostate cancer has spread to distant lymph nodes, bones or other organs, ADT becomes a central component of systemic treatment. ADT alone is no longer the only modern approach for many fit patients with metastatic hormone-sensitive prostate cancer.

Current EAU guidance recommends discussing combination treatment, including ADT plus an androgen receptor pathway inhibitor such as abiraterone plus prednisone, apalutamide, enzalutamide or darolutamide. Some patients may also be candidates for combinations involving chemotherapy ($1,500–$8,000+).

Some prostate cancers eventually continue growing despite testosterone being suppressed to castrate levels. This is castration-resistant prostate cancer (CRPC). ADT usually does not simply stop. Men with CRPC generally continue testosterone suppression while additional treatment is selected.

Treatment may include enzalutamide, abiraterone, chemotherapy, PARP inhibitors for selected genetic alterations, lutetium-177 PSMA therapy in appropriate patients, or other systemic treatments. The EAU recommends basing selection on symptoms, performance status, comorbidities, disease location and extent, genomic profile and previous treatments.

The appropriate medicine depends on the clinical setting rather than simply choosing the newest drug.

GnRH agonists are among the most established forms of medical ADT. They are generally given as injections or implants at intervals determined by the specific product — approximately monthly, or at longer intervals including every several months.

There can initially be a temporary rise in testosterone before testosterone subsequently falls to very low levels. This is called an androgen flare. In most patients it is manageable, but it can be clinically important in men with certain advanced cancers, particularly when there is concern about spinal cord compression or urinary obstruction. An older anti-androgen may sometimes be used temporarily when starting a GnRH agonist to reduce flare.

GnRH antagonists suppress testosterone without producing the same initial testosterone surge associated with GnRH agonists. Degarelix is administered by injection and can rapidly suppress testosterone. Relugolix is an oral GnRH antagonist taken daily.

The choice between an agonist and antagonist depends on the patient's disease, cardiovascular risk, convenience, medication adherence and other clinical factors. The EAU notes that GnRH antagonists may be particularly relevant in patients with cardiovascular disease or cardiovascular risk factors.

Androgen receptor inhibitors work further downstream. Instead of simply lowering testosterone, they interfere with the ability of androgens to activate the androgen receptor. Important newer drugs include enzalutamide, apalutamide and darolutamide, often called androgen receptor pathway inhibitors (ARPIs).

Enzalutamide can be used in several advanced settings, including selected men with metastatic hormone-sensitive disease, non-metastatic CRPC, metastatic CRPC and certain high-risk biochemical recurrence settings. Potential side effects include fatigue, hot flashes, diarrhea, high blood pressure, dizziness, falls and, rarely, seizures.

Apalutamide is used in selected patients with metastatic hormone-sensitive disease and non-metastatic castration-resistant disease. Possible adverse effects include fatigue, rash, hot flashes, falls, fractures and hypothyroidism in some patients. Its use is generally combined with testosterone suppression rather than used as a replacement for ADT in metastatic disease.

Darolutamide has a distinct molecular structure. The FDA expanded its indication to metastatic castration-sensitive prostate cancer in 2025, including use with ADT and in appropriate treatment combinations. Its central nervous system penetration is relatively limited compared with some other ARPIs. That does not mean it is free of side effects, but the adverse-effect profile can differ between ARPIs.

Abiraterone works differently. It blocks the CYP17 enzyme, which is involved in androgen production, reducing androgen production not only in the testicles but also through other steroid-producing pathways. It is usually given with a low dose of prednisone or another corticosteroid.

Potential adverse effects include high blood pressure, fluid retention, low potassium, liver abnormalities, fatigue and joint or muscle symptoms. Patients receiving abiraterone require appropriate monitoring.

In advanced disease, doctors may combine these approaches because prostate cancer can adapt to low testosterone and continue using the androgen receptor pathway.

There is no universal duration. The answer depends heavily on why ADT is being prescribed.

These are general treatment patterns, not prescriptions for an individual patient. The EAU recommends individualized follow-up based on stage, symptoms, prognostic factors and treatment.

In localized prostate cancer treated with curative-intent radiation, ADT may have a defined start and stop date. Metastatic disease is different. When prostate cancer has spread, ADT is often continued because maintaining low testosterone remains part of disease control. If the cancer later becomes castration-resistant, testosterone suppression is generally maintained while another systemic treatment is added.

Intermittent ADT means treatment is given for a period, stopped when certain criteria are reached, and restarted later when the disease shows signs of returning or progressing. The potential advantage is a treatment-free period during which some hormone-related side effects may improve. It is not appropriate for every patient or every stage.

Evidence summarized by the NCI has found no clear overall-survival difference between intermittent and continuous ADT across advanced/recurrent settings in a large systematic review, while some studies found improvements in physical and sexual functioning during treatment breaks. The decision has to be individualized.

Testosterone does not necessarily return immediately after stopping ADT. Recovery depends on age, duration of treatment, type of ADT, baseline testosterone, other treatments and individual biology. Some men recover testosterone substantially. Others, particularly after prolonged treatment, may have incomplete recovery. Sexual symptoms and some other effects may therefore persist even after treatment is stopped.

Most side effects are related to the reduction in testosterone. Common effects include hot flashes, night sweats, reduced sexual desire, erectile dysfunction, fatigue, weight gain, loss of muscle mass, reduced physical strength, bone loss, increased fracture risk, mood changes, breast enlargement or tenderness, changes in cholesterol, insulin resistance and anemia. The risk and severity vary between patients and generally increase with longer exposure to ADT.

Hot flashes can happen during the day or at night. Management can include regular physical activity, maintaining a healthy weight, avoiding known triggers, cooling strategies and selected medications when necessary.

ADT can have a major effect on sexual health: reduced sexual desire, difficulty achieving an erection, reduced spontaneous erections, changes in ejaculation and reduced sexual satisfaction. Medicines such as sildenafil may help some forms of erectile dysfunction, but they do not necessarily restore sexual desire caused by very low testosterone. Sexual health should be discussed openly before starting long-term ADT.

Long-term ADT can change body composition. Some men gain abdominal fat while losing muscle mass. Regular resistance exercise and aerobic activity can help. Practical eating notes are in Prostate Cancer Diet.

Testosterone plays an important role in maintaining bone health. Long-term ADT can reduce bone mineral density and increase fracture risk. Doctors may consider baseline bone mineral density testing, DEXA scanning, calcium and vitamin D assessment, weight-bearing exercise, resistance training, fall prevention and bone-protective medicines when indicated. Depending on fracture risk, medicines such as denosumab or bisphosphonates may be considered.

Long-term androgen deprivation can affect metabolic health: increased body fat, insulin resistance, changes in cholesterol, increased blood sugar and higher cardiovascular risk in some patients. The EAU recommends monitoring metabolic complications during ADT, including lipid profiles and HbA1c. Men with existing cardiovascular disease should make sure their oncology team knows their complete cardiac history.

ADT can contribute to insulin resistance. That does not mean every man receiving ADT will develop diabetes. Men with diabetes or prediabetes may need closer monitoring of blood glucose, HbA1c, weight, blood pressure and lipids. ADT may also alter lipid metabolism.

Some men experience irritability, low mood, reduced motivation, sleep problems, difficulty concentrating or memory complaints. Depression should not simply be accepted as an unavoidable part of cancer treatment. If significant mood or cognitive changes occur, they should be discussed with the treating team.

PSA remains an important marker, but it is not the only measurement. Doctors may monitor PSA, testosterone, blood count, liver and kidney function, blood glucose, HbA1c, lipid profile, bone mineral density, blood pressure, weight, symptoms and treatment-specific adverse effects.

The EAU recommends checking PSA and testosterone during ADT and monitoring for metabolic complications. In metastatic disease, follow-up may also include regular imaging because disease progression does not always produce an immediate PSA rise. PSMA PET is used in selected settings, not after every injection.

If prostate cancer appears to be progressing, doctors may measure testosterone to determine whether the cancer is truly progressing despite adequate androgen suppression. Castration-resistant prostate cancer is defined by progression despite castrate-level testosterone. The EAU currently uses a testosterone threshold of below 50 ng/dL (1.7 nmol/L) in this context.

A rising PSA may indicate that the cancer is becoming less responsive to the current hormonal treatment. PSA should be interpreted together with testosterone, imaging, symptoms, PSA trend, previous treatments and the location and extent of disease. A single PSA result should not automatically trigger a change in treatment.

CRPC develops when prostate cancer progresses despite testosterone being reduced to castrate levels. The cancer may produce or use small amounts of androgen more efficiently, increase androgen receptor activity, change androgen receptor signalling or use alternative growth pathways. This is why additional treatments may be needed even though testosterone remains very low.

The transition is not determined by PSA alone. Doctors use testosterone, PSA kinetics, imaging and the overall clinical picture.

Modern systemic therapy increasingly uses ADT plus an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide or darolutamide). For metastatic hormone-sensitive disease, current EAU guidance recommends combination treatment for fit patients rather than relying on ADT alone when there is no contraindication.

Yes. Some patients with metastatic hormone-sensitive prostate cancer may receive ADT + ARPI + docetaxel, often called triplet therapy. Chemotherapy is not appropriate for every patient. Doctors consider age, fitness, organ function, disease burden, symptoms, metastatic pattern, previous treatment and potential toxicity. The 2026 FDA review of the treatment landscape identifies ADT plus an ARPI as a standard combination approach for metastatic hormone-sensitive disease, with triplet therapy appropriate for selected patients.

ADT can be particularly important when radiation is being used for higher-risk prostate cancer: unfavorable intermediate-risk, high-risk, locally advanced and selected recurrent disease. For high-risk disease, long-term ADT may be combined with external-beam radiation, and selected treatment plans may also incorporate a brachytherapy boost.

ADT may be started before radiation (neoadjuvant ADT). This can lower testosterone, reduce cancer activity, sometimes reduce prostate volume and begin systemic treatment before radiation. ADT can also continue after radiation. The systemic component may help control microscopic disease that cannot be seen on imaging. See Radiation Therapy for Prostate Cancer.

ADT is not routinely required for every man undergoing radical prostatectomy. In selected high-risk situations, systemic therapy may be incorporated into a broader multimodal treatment strategy, but the decision depends heavily on pathology, imaging and risk characteristics. Hormone therapy should therefore not be considered a standard “pre-surgery medicine” for every prostate cancer patient. Radical prostatectomy planning ranges are $7,000–$18,000.

It can be, but not always. For a patient receiving ADT with radiation for localized high-risk disease, there may be a planned treatment duration. For metastatic disease, ADT is often continued long-term. For intermittent ADT, treatment is intentionally paused and restarted according to a predefined strategy. “How long will I need hormone therapy?” cannot be answered accurately without knowing the disease stage and treatment objective.

Yes. Lowering androgen activity can reduce prostate volume in some men. This can sometimes be useful when the prostate is large before radiation. Prostate shrinkage is not the primary objective of ADT in most prostate cancer treatment plans.

This distinction is important. Medicines used for benign prostate enlargement, such as finasteride or dutasteride, are not the same as ADT. They affect the conversion of testosterone to DHT and are commonly used for benign prostatic hyperplasia. They should not be confused with cancer-directed androgen deprivation therapy. Urinary symptoms from BPH are also not the same as an ADT indication.

No. Hormone therapy changes the hormonal environment that prostate cancer depends on. Chemotherapy uses cytotoxic medicines designed to kill or damage rapidly dividing cancer cells. Some patients receive both. Immunotherapy works by modifying immune-system activity against cancer and has a more limited and highly selected role in prostate cancer compared with ADT.

Cancer-related information may include PSA, Gleason score, Grade Group, biopsy findings, MRI, PSMA PET/CT or other staging imaging, CT and bone imaging. General health may include blood pressure, blood glucose, HbA1c, lipid profile, kidney and liver function and blood count. Long-term ADT assessment may include bone mineral density, fracture risk, cardiovascular history, existing diabetes, weight and current medications.

The EAU recommends healthy weight and diet, smoking cessation, appropriate calcium and vitamin D intake, and monitoring for metabolic complications during ADT.

Depending on fracture risk, doctors may prescribe denosumab, zoledronic acid or other bisphosphonates. These medicines are not automatically required for every patient. Some have uncommon but important complications, including osteonecrosis of the jaw. Dental assessment may therefore be appropriate before certain long-term treatments.

A history of heart attack, stroke, heart failure, arrhythmia, high blood pressure, diabetes or high cholesterol should be discussed with the oncology team. The choice of ADT and additional ARPI therapy may take cardiovascular risk into consideration. The EAU notes differences in cardiovascular adverse-effect profiles among ARPIs and emphasizes consideration of comorbidities when selecting treatment.

There is no single fixed cost. The total expense depends on the medicine used, brand or formulation, injection frequency, oral versus injectable treatment, duration, whether an ARPI is added, whether prednisone is required with abiraterone, monitoring and laboratory tests, hospital, and whether treatment is part of a larger plan.

GAF Healthcare’s published planning range for hormone therapy is $1,000–$4,500. Traditional ADT injections can have a very different cost from newer oral androgen receptor pathway inhibitors. For international patients, the quotation should be based on the specific drug, dose, frequency and planned duration, rather than a generic “hormone therapy cost.” City pages such as Delhi NCR hormone therapy use the same national range unless a hospital issues a verified quotation.

Digital copies are useful, but original pathology material can be particularly valuable when a second pathology review is requested.

There is no single “best hormone medicine.” Doctors usually consider stage, hormone sensitivity, cardiovascular health, bone health, kidney and liver function, other medicines, disease burden, previous treatment and genomic findings. The 2026 EAU guidelines specifically recommend considering performance status, symptoms, comorbidities, disease extent, genomic profile, patient preferences and previous treatment when selecting systemic therapy for advanced disease. See treatment options.

Patients receiving treatment for advanced prostate cancer should seek urgent medical attention for new severe back pain, new weakness or numbness in the legs, difficulty walking, loss of bladder or bowel control, sudden inability to pass urine, severe bone pain, chest pain or severe shortness of breath.

New neurological symptoms in a patient with prostate cancer that has spread to the bones can indicate possible spinal cord compression and require urgent assessment in a local emergency department — not a delayed WhatsApp message.

Hormone therapy has changed substantially over the last several years. Traditional ADT remains an important part of prostate cancer treatment, but modern management increasingly combines testosterone suppression with medicines that target the androgen receptor pathway.

The right approach depends on whether the cancer is localized, high-risk, locally advanced, recurrent, metastatic hormone-sensitive or castration-resistant. The duration of ADT is equally individualized. A patient receiving radiation for high-risk localized disease may have a planned course lasting years, while a patient with metastatic disease may remain on ADT long-term.

Side-effect management should be considered part of treatment rather than an afterthought. Bone health, cardiovascular risk, metabolic health, sexual function, physical activity and emotional wellbeing all deserve attention during long-term therapy.

For patients considering treatment in India, the most useful starting point is a review of the complete cancer record—including pathology, PSA history and staging scans—followed by a consultation with a qualified urologic oncologist or medical/radiation oncologist. The treatment plan should be based on the disease characteristics rather than on a particular drug alone.

It can last several months, 18–36 months in some radiation-treatment plans, or indefinitely in many patients with metastatic disease. The duration depends on the stage and treatment strategy.

ADT is one of the main forms of hormone therapy. The broader term “hormone therapy” can also include medicines that block androgen receptors or androgen production.

Leuprolide, goserelin and triptorelin are commonly used GnRH agonists. Degarelix is a GnRH antagonist. Availability varies by country and hospital.

Yes. Relugolix is an oral GnRH antagonist. Other oral hormonal medicines, including enzalutamide, apalutamide, darolutamide and abiraterone, work through different mechanisms.

It can. Reduced testosterone can lower sexual desire and make erections difficult. These effects can be significant during treatment.

Weight gain, particularly increased body fat, can occur. Loss of muscle mass can occur at the same time.

Yes. Regular aerobic and resistance exercise can help with muscle loss, weight management, fatigue, physical function and some metabolic effects.

Long-term ADT can reduce bone mineral density and increase fracture risk. Bone health should therefore be assessed and monitored.

In hormone-sensitive prostate cancer, PSA often falls when treatment is effective. However, PSA response varies and must be interpreted alongside testosterone, imaging and symptoms.

Doctors may check testosterone to confirm adequate androgen suppression and may order imaging to determine whether the cancer has progressed. The next treatment depends on whether the cancer is hormone-sensitive or castration-resistant.

Sometimes. A defined treatment course may be stopped after the planned duration. Intermittent ADT can also involve treatment breaks in selected patients. However, patients should never stop ADT on their own.

It can recover after treatment stops, but recovery varies. After prolonged treatment, testosterone may not return fully to its previous level.

Yes. Some prostate cancers eventually progress despite very low testosterone. This is known as castration-resistant prostate cancer.

Yes. ADT is commonly combined with radiation for selected unfavorable intermediate-risk, high-risk and locally advanced prostate cancers.

It may be used in selected patients, particularly when there are high-risk pathological or nodal features or when recurrence develops. The decision is individualized.

Yes. ADT is a foundation of treatment for metastatic prostate cancer. Current treatment often adds another systemic medicine such as an ARPI for suitable patients.

This article is the ADT hub. Other cluster pages keep their own search intent:

GAF Healthcare coordinates international patients who need an ADT or ARPI plan in India — with radiation, after a rising PSA, or for metastatic disease. Share the PSA timeline, the full biopsy PDF, Grade Group, staging scans including PSMA PET if performed, cardiovascular and bone-health history, and the current medicine list. A coordinator can introduce a medical oncologist and, when radiation is part of the plan, a radiation oncologist, then help collect an itemised quotation covering the drug, dose, frequency, labs and planned duration.

This article is intended for general educational purposes and should not replace consultation with a qualified medical professional. Prostate cancer treatment is highly individualized. The choice of hormone therapy, medicine, combination treatment and duration depends on the cancer stage, pathology, imaging, previous treatment, overall health and other clinical factors.

Drug availability and regulatory approvals can also vary by country. Patients should not start, stop or change cancer treatment without discussing it with their treating doctor.

1. NCI — Hormone Therapy for Prostate Cancer — how ADT works, medicines and common side effects.

2. EAU Guidelines — Prostate Cancer Treatment — combination ADT plus ARPI, duration and follow-up.

3. American Cancer Society — Hormone Therapy for Prostate Cancer — types of hormone therapy and what to expect.

4. FDA — Prostate Cancer: Symptoms, Tests and Treatments — consumer-facing treatment landscape including hormonal medicines.

5. NCI — Prostate Cancer Treatment (PDQ) — stage-specific use of hormone therapy.

Last reviewed against the cited sources: September 2026.